Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBS-NN vaccine in healthy female volunteers
NCT02459262Phase 1Completed
- Sponsor
- MinervaX
- Start
- May 2015
- Primary completion
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GBS-NN/NN2 vaccine in Group B streptococcal infection (GBS), sponsored by MinervaX. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (Part A) at 12 weeks. Started May 2015; status: completed.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
Group B streptococcal infection (GBS)
Beyond the preview
Go deeper on NCT02459262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02459262.